| Tuesday | Wednesday | Thursday | Friday
|
Saturday
|
| FRIDAY, DECEMBER 9, 2022 |
| All times are CENTRAL Time |
|
| |
|
| 7:00 am - 8:15 am CT |
POSTER SESSION #6 - Hall 1
|
| 7:00 am - 8:15 am CT |
SPOTLIGHT POSTER DISCUSSION SESSION #16 - Hemisfair Ballroom 1&2
Imaging to Diagnose Breast Cancer and Direct Its Treatment: Who, When, and How?
Chair: Janie Lee, MD, MSc
Seattle Cancer Care Alliance
Seattle, WA
and
David A. Mankoff, MD, PhD
University of Pennsylvania
Philadelphia, PA
Disparities in utilization
Janie Lee, MD, MSc
Seattle Cancer Care Alliance
Seattle, WA
Imaging to guide treatment
Amy Fowler, MD, PhD, FSBI
University of Wisconsin
Madison, WI
AI/Radiomics and novel metrics applied and breast cancer imaging
Aimilia Gastounioti, PhD
Washington University School of Medicine
St. Louis, MO
Patient Advocate
Jeri Francoeur, PA
Alamo Breast Cancer Foundation
Ormond Beach, FL
|
| 7:00 am - 8:15 am CT |
SPOTLIGHT POSTER DISCUSSION SESSION #17 - Stars at Night Ballrooms 1&2
Endocrine Therapy New Insights
Chair: Lajos Pusztai, MD, DPhil
Yale School of Medicine
New Haven, CT
Pavani Chalasani, MD, MPH
University of Arizona Cancer Center
Tucson, AZ
Seth A. Wander, MD, PhD
Massachusetts General Hospital
Cambridge, MA
|
| 7:00 am - 8:15 am CT |
SPOTLIGHT POSTER DISCUSSION SESSION #18 - Stars at Night Ballrooms 3&4
Updates and New Therapies for HER2 Positive Disease
Chair: Ian E. Krop, MD, PhD
Yale School of Medicine
New Haven, CT
Roisin M. Connolly, MD
University College Cork
Cork, Ireland
Sara A. Hurvitz, MD, FACP
University of California
Los Angeles, CA
Paula R. Pohlmann, MD, MSc, PhD
UT MD Anderson Cancer Center
Houston, TX
Vernal Branch
UNC Chapel Hill Lineberger Cancer Institute
Mooresville, NC
|
| 8:30 am - 9:00 am CT |
AACR OUTSTANDING INVESTIGATOR AWARD FOR BREAST CANCER RESEARCH, supported by the Breast Cancer Research Foundation- Hall 3
Moderator: Abenaa M. Brewster, MD
UT MD Anderson Cancer Center
Houston, TX
Breast Cancer Prevention in Premenopausal Women: Accelerating Transition from Discoveries to Clinical Translation
Adetunji T. Toriola, MD, PhD, MPH
Washington University School of Medicine
St. Louis, MO |
| |
|
| 9:00 am - 11:30 am CT |
GENERAL SESSION #4 - Hall 3
Moderators:
Julie Nangia, MD
Baylor College of Medicine
Houston, TX
Wendy A. Woodward, MD, PhD
UT MD Anderson Cancer Center
Houston, TX
|
| 9:00 am - 9:15 am CT |
GS4-01 Impact of breast conservation therapy on local recurrence in patients with multiple ipsilateral breast cancer – Results from ACOSOG Z11102 (Alliance)
Boughey JC, Rosenkranz KM, Ballman KV, McCall L, Haffty BG, Cuttino LW, Kubicky CD, Le-Petross HTC, Van Zee K, Giuliano AE, Hahn OM, Hunt KK, Carey LA, Partridge AH. Division of Breast and Melanoma Surgical Oncology, Department of Surgery; Mayo Clinic, Rochester, MN, USA; Geisel School of Medicine, Dartmouth-Hitchcock Medical Center; Weill Cornell Medicine; Duke University; Rutgers Cancer Institute of New New Jersey; Sarah Cannon Cancer Institute at Henrico Doctors' Hospital; Sutter Medical Group; The University of Texas MD Anderson Cancer Center; Memorial Sloan-Kettering Cancer Center; Cedars-Sinai Medical Center; Alliance for Clinical Trials in Oncology Operations Office; Alliance for Clinical Trials in Oncology; Dana-Farber Cancer Institute, Boston, MA, USA. |
| 9:15 am - 9:30 am CT |
GS4-02 Oncological outcomes following omission of axillary lymph node dissection in node positive patients downstaging to node negative with neoadjuvant chemotherapy: the OPBC-04/EUBREAST-06/OMA study
Montagna G, Mrdutt M, Botty A, Barrio AV, Sevilimedu V, Boughey JC, Hoskin TL, Rosenberger LH, Hwang ES, Inhgam A, Papassotiropoulos B, Nguyen-Sträuli BD, Kurzeder C, Diaz Aybar D, Vorburger D, Matlac DM, Ostapenko E, Riedel F, Fitzal F, Meani F, Fick F, Sagasser J, Heil J, Dedes KJ, Romics L, Banys-Paluchowski M, Cueva Perez MDR, Chavez Diaz M, Heidinger M, Fehr MK, Reinisch M, Maggi N, Rocco N, Ditsch N, Gentilini OD, Resende Paulinelli R, Zarhi SS, Küemmel S, Bruzas S, Di Lascio S, Parissenti T, Güth U, Ovalle V, Tausch C, Morrow M, Kühn T, Weber WP. Breast Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Surgery, Duke University Medical Center, Durham, NC, USA; Memorial Sloan Kettering Cancer Center; Division of Breast and Melanoma Surgical Oncology, Department of Surgery, Mayo Clinic, Rochester, MN, USA; Department of Surgery, Division of Breast and Melanoma Surgical Oncology, Mayo Clinic, Rochester, MN, USA; University of Glasgow and NHS Greater Glasgow and Clyde, Department of Academic Surgery, Glasgow, UK; Breast Center Zurich AG, Zurich, Switzerland; Department of Gynecology, University Hospital Zurich, Zurich, Switzerland; Breast Center, University Hospital of Basel, Basel, Switzerland; Guillermo Almenara Irigoyen National Hospital Lima, Lima, Peru; Breast Cancer Unit, Comprehensive Cancer Center Zurich, University Hospital Zurich, Zurich, Switzerland; Department of Gynecology and Obstetrics, University of Schleswig-Holstein Campus Lübeck, Lübeck, Germany; Department of General Surgery and Breast Health Center, Medical University of Vienna, Vienna, Austria; Faculty of Medicine, Vilnius University, Vilnius, Lithuania; Department of Gynecology and Obstetrics, Breast Unit, Heidelberg University Hospital, Heidelberg, Germany; Division of General Surgery, Department of Surgery, Medical University of Vienna, Vienna, Austria; Centro di Senologia della Svizzera Italiana, Ente Ospedaliero Cantonale, Lugano, Switzerland; Department of Gynecology and Obstetrics, University of Schleswig-Holstein Campus Lübeck, Lübeck, Germany; Department of Obstetrics and Gynecology, University Hospital of Augsburg, Augsburg, Germany; Department of Gynecology and Obstetrics, Breast Unit, Heidelberg University Hospital, Heidelberg, Germany; Breast Cancer Center, University Hospital of Zurich, Zurich, Switzerland; Department of Academic Surgery, Gartnavel General Hospital Glasgow,University of Glasgow, Glasgow, UK; Department of Gynecology and Obstetrics, University of Schleswig-Holstein Campus Lübeck, Lübeck, Germany; Guillermo Almenara Irigoyen National Hospital Lima, Lima, Peru; Breast Center, University Hospital of Basel, Basel, Switzerland; Breast Center Thurgau, Münsterlingen, Switzerland; Interdisciplinary Breast Cancer Center/ Breast Unit, Essen, Germany; Breast Center, University Hospital of Basel, Basel, Switzerland; Department of Advanced Biomedical Sciences, University Federico II, Naples, Italy; Department of Gynaecology and Obstetrics, University Hospital Augsburg, Augsburg, Germany; Breast Surgery Unit, San Raffaele University Hospital, Milan, Italy; Federal University of Goiás, Araujo Jorge Cancer Hospital, Goiás, Brazil; Department of Radiation Oncology, University Diego Portales – IRAM, Santiago, Chile; Breast Unit, Kliniken Essen-Mitte, Essen, Germany; Breast Unit, Hospital Essen-Mitte, Essen, Germany; Service of medical oncology, Oncology Institute of Southern Switzerland, EOC, Bellinzona, Switzerland; Women's Clinic Cantonal Hospital Frauenfeld, Switzerland; Breast Center Zurich, Zurich, Switzerland; University of Basel, Basel, Switzerland; Department of Radiation Oncology, University Diego Portales – IRAM, Santiago, Chile; Breast Center Zurich, Zurich, Switzerland; Memorial Sloan Kettering Cancer Center; Department of Gynecology, Hospital Esslingen, Esslingen, Germany; Breast Center, University Hospital of Basel, Basel, Switzerland. |
| 9:30 am - 9:45 am CT |
GS4-03 Validation of Profile for the Omission of Local Adjuvant Radiotherapy (POLAR) in a meta-analysis of three randomized controlled trials of breast conserving surgery +/- radiotherapy
Karlsson P, Fyles A, Chang SL, Arrick B, Baehner F, Malmström P, Fernö M, Holmberg E, Sjöström M, Liu F-F, Cameron DA, Williams LJ, Bartlett JMS, Dunlop J, Caldwell J, Loane JF, Mallon E, Piper T, Jack WJ, Kunkler I, Feng FY, Speers CW, Pierce LJ, Bennett J, Taylor KJ. Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; Princess Margaret Cancer Centre and University of Toronto, Toronto, ON, Canada; Exact Sciences; Division of Oncology, Department of Clinical Sciences Lund, Lund University, Sweden; Department of Haematology, Oncology and Radiation Physics, Skåne University Hospital, Lund, Sweden; Division of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; Division of Oncology, Department of Clinical Sciences Lund, Lund University, Sweden; Department of Radiation Oncology, University of California San Francisco, San Francisco, CA; The University of Edinburgh, Edinburgh Cancer Research; Edinburgh Clinical Trials Unit, University of Edinburgh; University of Edinburgh, Scotland, United Kingdom; Scottish Clinical Trials Research Unit (SCTRU); Public Health Scotland; Queen Elizabeth University Hospital, Glasgow; University of Glasgow - Institute of Cancer Sciences, NHS Lothian; Department of Radiation Oncology, University of California San Francisco, San Francisco, CA; University of Michigan; University of Edinburgh Cancer Research Centre, Institute of Genetics and Cancer. |
| 9:45 am - 10:00 am CT |
GS4-04 Population-based estimates of contralateral breast cancer risk among carriers of germline pathogenic variants in ATM, BRCA1, BRCA2, CHEK2, and PALB2
Yadav S, Boddicker NJ, Na J, Polley EC, Hu C, Hart SN, Gnanaolivu RD, Larson N, Dunn C, Holtegaard S, Huang H, Teras LR, Patel AV, Lacey Jr JV, Neuhausen S, Bernstein L, Martinez E, Haiman C, Chen F, Ruddy KJ, Olson J, John E, Kurian AW, Sandler DP, O'Brien KM, Taylor JA, Weinberg CR, Anton-Culver H, Ziogas A, Zirpoli GR, Goldgar DE, Nathanson KL, Domchek SM, Palmer JR, Weitzel J, Kraft P, Couch FJ. Mayo Clinic; University of Chicago; American Cancer Society; City of Hope, University of California, San Diego; University of Southern California; Mayo Clinic, Rochester, USA, Stanford University; Stanford Cancer Institute, Stanford University School of Medicine, Stanford CA; National Institute of Environmental Health Sciences; University of California, Irvine; Boston University; University of Utah; University of Pennsylvania School of Medicine; Latin American School of Medicine; Harvard University T.H. Chan School of Public Health. |
| 10:00 am - 10:15 am CT |
GS4-05 Phase II randomized trial of conventional versus hypofractionated post-mastectomy proton radiotherapy
Mutter R, Giri S, Fruth B, Remmes N, Anand A, Ruddy KJ, Villarraga H, Santos Patarroyo S, Yan E, Merrell K, McGee L, Vern-Gross T, Stish B, Gao R, Boughey JC, Park S, Corbin K, Vargas C. Mayo Clinic, Rochester, MN, USA; Mayo Clinic; Division of Breast and Melanoma Surgical Oncology, Department of Surgery,Mayo Clinic, Rochester, MN, USA; Department of Radiation Oncology, Mayo Clinic Rochester Campus. |
| 10:15 am - 10:30 am CT |
GS4-06 Radiomic phenotypes of breast texture and association with breast cancer risk and masking
Winham S, McCarthy AM, Gastounioti A, Scott C, Norman A, Mankowski WC, Pantalone L, Jensen M, Cohen EA, Horng H, Brandt K, Conant EF, Kerlikowski K, Kontos D, Vachon C. Mayo Clinic; University of Pennsylvania; Washington University in St. Louis; University of California, San Francisco; University of Pennsylvania, Department of Radiology. |
| 10:30 am - 10:45 am CT |
GS4-07 Discussant for GS4-06
David A. Mankoff, MD, PhD
University of Pennsylvania
Philadelphia, PA
|
| 10:45 am - 11:00 am CT |
GS4-08 10-year results of a phase 3 trial of low-dose tamoxifen in non-invasive breast cancer
De Censi A, Lazzeroni M, Puntoni M, Boni L, Guerrieri Gonzaga A, Buttiron Webber T, Fava M, Briata IM, Giordano L, Digennaro M, Cortesi L, Falcini F, Avino F, Millo F, Cagossi K, Gallerani E, De Simone A, Cariello A, Aprile G, Renne M, Bonanni B. E.O. Ospedali Galliera, Genova, Italy; IEO - European Institute of Oncology IRCCS, Milan; Clinical & Epidemiological Research Unit, University Hospital of Parma; IRCCS Ospedale Policlinico San Martino, Genoa; Azienda Ospedaliera-Universitaria Città della Salute e della Scienza di Torino; IRCCS Istituto Tumori Giovanni Paolo II, Bari; Azienda Ospedaliera-Universitaria Policlinico di Modena; Ospedale Morgagni-Pierantoni, Forlì; Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Naples; Ospedali riuniti ASL AL - Ospedale SS. Antonio e Margherita, Tortona (AL); Ospedale Bernardino Ramazzini, Carpi; ASST Settelaghi Varese; ICS Maugeri -Centro Medico di Pavia; Ospedale Santa Maria delle Croci, Ravenna; Azienda ULSS 8 Berica- Ospedale di Vicenza; Chirurgia Generale Azienda Ospedaliera Mater Domini Catanzaro; Division of Cancer Prevention and Genetics, European Institute of Oncology, IRCCS, Milan, Italy. |
| 11:00 am - 11:15 am CT |
GS4-09 Pregnancy Outcome and Safety of Interrupting Therapy for women with endocrine responsIVE breast cancer: Primary Results from the POSITIVE Trial (IBCSG 48-14 / BIG 8-13)
Partridge AH, Niman SM, Ruggeri M, Peccatori FA, Azim Jr HA, Colleoni M, Saura C, Shimizu C, Sætersdal AB, Kroep JR, Mailliez A, Warner E, Borges VF, Amant F, Gombos A, Kataoka A, Rousset-Jablonski C, Borstnar S, Takei J, Lee JE, Walshe JM, Ruiz Borrego M, Moore HCF, Saunders C, Bjelic-Radisci V, Susnjar S, Cardoso F, Smith KL, Ferreiro T, Ribi K, Ruddy KJ, El-Abed S, Piccart M, Korde LA, Goldhirsch A, Gelber RD, Pagani O (Presenting Author). POSITIVE Investigators, International Breast Cancer Study Group (a division of ETOP IBCSG Partners Foundation) Alliance for Clinical Trials in Oncology, Breast International Group, U.S. NCI National Clinical Trials Network. |
| 11:15 am - 11:30 am CT |
GS4-10 Discussant for GS4-09
Jennifer K. Litton, MD
UT MD Anderson Cancer Center
Houston, TX |
| |
|
| 10:00 am - 5:00 pm CT |
EXHIBITS - Hall 2 |
| |
|
| 11:30 am - 12:00 pm CT |
BRINKER AWARD FOR SCIENTIFIC DISTINCTION IN CLINICAL RESEARCH
Moderator: Ann Partridge, MD, MPH
Dana-Farber Cancer Institute
Boston, MA
The Contribution of NSABP Clinical Trials to the Management of Early Breast Cancer: PAST AS PROLOGUE
Norman Wolmark, MD, FACS, FRCSC
UPMC Hillman Cancer Center/University of Pittsburgh and NRG Oncology
Pittsburgh, PA |
| |
|
| 12:00 pm - 3:00 pm CT |
GENERAL SESSION #5 - Hall 3
Moderators:
Banu K. Arun, MD
UT MD Anderson Cancer Center
Houston, TX
and
Alexander JR Bishop, PhD
UT Health San Antonio
San Antonio, TX
|
| 12:00 pm - 12:15 pm CT |
GS5-01 Addition of platinum to sequential taxane-anthracycline neoadjuvant chemotherapy in patients with triple-negative breast cancer: A phase III randomized controlled trial
Gupta S, Nair NS, Hawaldar R, Vanmali V, Parmar V, Gulia S, Ghosh J, Joshi S, Sarin R, Wadasadawala T, Panhale T, Desai S, Shet T, Patil A, Chitkara G, Rath S, Bajpai J, Thakkur M, Badwe R. Tata Memorial Centre; Tata Memorial Hospital. |
| 12:15 pm - 12:30 pm CT |
GS5-02 Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency – long-term survival of the GeparOLA study
Fasching PA, Schmatloch S, Hauke J, Rey J, Jackisch C, Klare P, Link T, Hanusch C, Huober J, Stefek A, Seiler S, Schmitt WD, Uleer C, Doering G, Rhiem K, Schneeweiss A, Denkert C, Schmutzler RK, Hahnen E, Untch M, Nekljudova V, Blohmer J-U, Loibl S. Department of Obstetrics and Gynecology, University Hospital Erlangen, Erlangen, Germany; Elisabeth Krankenhaus Kassel, Germany; Zentrum Familiärer Brust- und Eierstockkrebs, Uniklinik Köln, Germany; GBG Forschungs GmbH; Department of Obstetrics and Gynecology, Sana Klinikum Offenbach, Germany; MediOnko-Institut GbR Berlin; Department of Gynecology and Obstetrics, Technische Universität Dresden, Dresden, Germany; Rotkreuzklinikum München, Germany; Kantonsspital St.Gallen, Brustzentrum, Departement Interdisziplinäre medizinische Dienste, St. Gallen, Switzerland; Johanniter-Krankenhaus Genthin-Stendal, Germany; German Breast Group, Neu-Isenburg, Germany; Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt Universität zu Berlin, Institute of Pathology, Berlin, Germany; Gemeinschaftspraxis Hildesheim, Germany; Hämato-Onkologie im Medicum Bremen, Germany; Zentrum Familiärer Brust- und Eierstockkrebs, Uniklinik Köln, Germany; National Center for Tumor Diseases, Heidelberg University Hospital and German Cancer Research Center, Heidelberg, Germany; Institut für Pathologie, Philipps Universität Marburg und Universitätsklinikum Marburg (UKGM), Germany; Zentrum Familiärer Brust- und Eierstockkrebs, Uniklinik Köln, Germany; Zentrum Familiärer Brust- und Eierstockkrebs, Uniklinik Köln, Germany; Helios Klinikum Berlin-Buch, Berlin, Germany; German Breast Group, Neu-Isenburg, Germany; Charité - Universitätsmedizin Berlin; GBG Forschungs GmbH, Neu-Isenburg, Germany.
|
| 12:30 pm - 12:45 pm CT |
GS5-03 Evaluation of anti-PD-1 Cemiplimab plus anti-LAG-3 REGN3767 in early-stage, high-risk HER2-negative breast cancer: Results from the neoadjuvant I-SPY 2 TRIAL
Isaacs C, Nanda R, Chien J, Trivedi MS, Stringer-Reasor E, Vaklavas C, Boughey JC, Sanford A, Wallace A, Clark AS, Thomas A, Albain KS, Kennedy LC, Sanft TB, Kalinsky K, Han HS, Williams N, Arora M, Elias A, Falkson C, Asare S, Lu R, Pitsouni M, Wilson A, Perlmutter J, Rugo HS, Schwab R, Symmans WF, Hylton NL, Van 't Veer L, Yee D, DeMichele A, Berry D, Esserman LJ, I-SPY Investigators. Georgetown University; University of Chicago, Chicago, IL, USA; University of California, San Francisco; Columbia University Irving Medical Center; University of Alabama Comprehensive Cancer Center, Birmingham, AL, USA; Huntsman Cancer Institute; Division of Breast and Melanoma Surgical Oncology, Department of Surgery, Mayo Clinic, Rochester, MN, USA; Sanford Health; University of California San Diego; University of Pennsylvania; Atrium Health Wake Forest Baptist Health; Loyola University Chicago Stritch School of Medicine, Cardinal Bernardin Cancer Center; Vanderbilt University Medical Center; Yale School of Medicine; Winship Cancer Institute at Emory University, Atlanta, GA, USA; H. Lee Moffitt Cancer Center, Tampa, FL, USA; The Ohio State University Comprehensive Cancer Center; UC Davis Comprehensive Cancer Center; University of Colorado Anschutz Medical Center; Wilmot Cancer Institute, University of Rochester Medical Center; Quantum Leap Healthcare Cooperative; Gemini Group; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA; The University of Texas MD Anderson Cancer Center; Masonic Cancer Center, University of Minnesota; Abramson Cancer Center, University of Pennsylvania; Berry Consultants, LLC. |
| 12:45 pm - 1:00 pm CT |
GS5-04 Identification of symptoms that are associated with irAEs in the I-SPY clinical trial
Basu A, Umashankar S, Melisko M, Lu R, Yu H, Yau C, Asare S, Pitsouni M, Shatsky RA, Isaacs C, DeMichele A, Hershman DL, Nanda R, Kim M-O, Esserman LJ, Rugo HS. University of California, San Francisco; Quantum Leap Healthcare Collaborative; University of California, San Francisco and Buck Institute for Research on Aging, Novato, California; Georgetown University; Abramson Cancer Center, University of Pennsylvania; Columbia University Irving Medical Center; University of Chicago, Chicago, IL, USA; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA. |
| 1:00 pm - 1:15 pm CT |
GS5-05 ZNF689 deficiency promotes intratumor heterogeneity and resistance to immune checkpoint blockade in triple-negative breast cancer
Ge L-P, Jin X, Di G-H, Jiang J-Z,Shao Z-M. Fudan University Shanghai Cancer Center; Department of Breast Surgery, Fudan University Shanghai Cancer Center; Key Laboratory of Breast Cancer in Shanghai, Department of Oncology, Shanghai Medical College, Fudan University. |
| 1:15 pm - 1:30 pm CT |
GS5-06 InteractPrint predicts clinically meaningful interactions between cancer epithelial cells and immune cells: Lessons from a single-cell breast cancer atlas
Xu L, Saunders K, Knutsdottir H, Chen K, Maués J, Hodgdon C, Roussos Torres ET, Reddy SM, Xu L, Chan I. UT Southwestern; UT Southwestern, University of Texas at Dallas; Johns Hopkins University; Unversity of Texas Southwestern Medical Center; Grasp Cancer; University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA. |
| 1:30 pm - 1:45 pm CT |
GS5-07 Estradiol represses anti-tumoral immune response to promote progression of triple-negative breast cancer brain metastases
Contreras-Zarate MJ, Alvarez-Eraso K, Tesic V, Tsuji N, Chafee L, Karam S, Ormond DR, Kabos P, Cittelly DM. University of Colorado, Aurora, CO, USA; University of Colorado Anschutz Medical Campus. |
| 1:45 pm - 2:00 pm CT |
GS5-08 Soluble E-cadherin: a novel prognostic biomarker and driver of brain metastasis in inflammatory breast cancer
Hu X, Xiong Y, Villodre ES, Song J, Manyam GC, Tacam MJ, Wang J, Bartholomeusz C, Tripathy D, Ueno NT, Woodward WA, Krishnamurthy S, Chen J, Debeb B. The University of Texas MD Anderson Cancer Center, Houston, TX, USA. |
| 2:00 pm - 2:15 pm CT |
GS5-09 Discussant for GS5-07 and GS 5-08
Nancy U. Lin, MD
Dana-Farber Cancer Institute
Boston, MA |
| 2:15 pm - 2:30 pm CT |
GS5-10 Utility of the 70-gene MammaPrint test for prediction of extended endocrine therapy benefit in patients with early-stage breast cancer in the IDEAL Trial
Liefers G-J, Meershoek-Klein Kranenbarg E, Duijm-de Carpentier M, J.H. van de Velde C, Kleijn M, Dreezen C, Menicucci A, van't Veer L (Presenter), Audeh W. Department of Surgery, Leiden University Medical Center; Agendia, NV, Amsterdam; Agendia Inc; Department of Laboratory Medicine, Department of Surgery, University of San Francisco.
|
| 2:30 pm - 2:45 pm CT |
GS5-12 Hypofractionated Radiotherapy in patients with Breast Cancer (HRBC): Acute toxicity data of a phase III randomized study
Yadav BS, Dahiya D, Gupta M. Post Graduate Institute of Medical Education & Research; Indira Gandhi Medical College.
|
| 3:00 pm - 5:00 pm CT |
EDUCATIONAL SESSION BLOCK #4
EDUCATIONAL SESSION BLOCK #4A - Stars at Night Ballroom 1&2
Advances in Pregnancy Associated Breast Cancer (PABC) - People's Choice
Moderator: Kalliopi Siziopikou, MD, PhD
Northwestern University
Chicago, IL
Updates in the pathology of PABC
Kalliopi Siziopikou, MD, PhD
Northwestern University
Chicago, IL
Special treatment issues in this young patient population
Ann Partridge, MD, MPH
Dana-Farber Cancer Institute
Boston, MA
Oncofertility and other quality of life issues
Matteo Lambertini, MD, PhD
University of Genova - San Martino Hospital
Genova, Italy
EDUCATIONAL SESSION BLOCK #4B - Stars at Night Ballroom 3&4
State of the Art Radiotherapy: Reducing Toxicity and Increasing Options
Moderator: Wendy Woodward, MD, PhD
UT MD Anderson Cancer Center
Houston, TX
Overview of the current state of the art - what patients and oncologists need to know
Rachel Jimenez, MD
Massachusetts General Hospital
Boston, MA
The role of advanced radiation technology in reducing toxicity
Melissa Mitchell, MD, PhD
UT MD Anderson Cancer Center
Houston, TX
Evidence for ablative radiation in metastatic breast cancer
Chiaojung Jillian Tsai, MD, PhD
Princess Margaret Cancer Centre
New York, NY
EDUCATIONAL SESSION BLOCK #4C - Hemisfair Ballroom 1&2
Targeting the Tumor Microenvironment for Clinical Impact
Moderator: Diana Cittelly, PhD
University of Colorado Anschutz Medical Campus
Aurora, CO
Influence of bone microenvironment on metastasis
Igor Bado, PhD
Baylor College of Medicine
Houston, TX
The contribution of the tumor microenvironment to cancer dormancy
Jose Javier Bravo-Cordero, PhD
Icahn School of Medicine at Mount Sinai
New York, NY
Effects of age on the tumor microenvironment
Sandra S. McAllister, PhD
Harvard Institutes of Medicine
Boston, MA
Can inflammation be targeted?
Angela DeMichele, MD, MSCE
University of Pennsylvania
Philadelphia, PA
|
| 5:00 pm - 5:15 pm CT |
REFRESHMENT BREAK |
| 5:15 pm - 7:15 pm CT |
View from the Trenches: What will You do on Monday Morning? - Stars at Night Ballroom 1&2
Moderators: Andrea Barrio, MD, FACS
Memorial Sloan Kettering Cancer Center
New York, NY
and
Moderator: Sara Tolaney, MD, MPH
Dana-Farber Cancer Institute
Boston, MA
Panelist:
Vernal Branch
Patient Advocate
UNC Chapel Hill Lineberger Cancer Institute
Mooresville, NC
Marianna Chavez, MD, MSC, FASCO
UT MD Anderson Cancer Center
Houston, TX
Tanja N. Fehm, MD
University Hospital Düsseldorf
Düsseldorf, Germany
Meredith Regan, DSc
Dana-Farber Cancer Institute
Boston, MA
Kalliopi Siziopikou, MD, PhD
Northwestern University
Chicago, IL
Mediget Teshome, MD, MPH, FACS
UT MD Anderson Cancer Center
Houston, TX
Cynthia Villreal Garza, MD, PhD
Tecnológico
de Monterrey
Nuevo Leon, Mexico
Richard
C. Zellars, MD
Indiana University
Indianapolis, IN
|
|